ATTAINMENT OF LDL-C TREATMENT TARGET IN FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS: A THEORETICAL MODEL EXPLORING EFFICACY OF CURRENT AND NOVEL LIPID LOWERING THERAPIES

被引：1
|
作者：
Hartgers, M. L. [1 ]
Besseling, J. [1 ]
Hovingh, G. K. [1 ]
机构：
[1] Acad Med Ctr, Vasc Med, Amsterdam, Netherlands
来源：
ATHEROSCLEROSIS | 2016年 / 252卷
关键词：
D O I：
10.1016/j.atherosclerosis.2016.07.372
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EAS16-0724
引用
收藏
页码：E43 / E44
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
    Kastelein, John J. P.
    Robinson, Jennifer G.
    Farnier, Michel
    Krempf, Michel
    Langslet, Gisle
    Lorenzato, Christelle
    Gipe, Daniel A.
    Baccara-Dinet, Marie T.
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (03) : 281 - 289
  • [42] Are coronary patients on lipid-lowering therapy in Europe achieving the recommended LDL-C target? Results from the Dyslipidemia International Study (DYSIS) II Europe
    Gitt, A. K.
    Ferrieres, J.
    De Ferrari, G.
    Elisaf, M.
    Hermans, M. P.
    Kiernan, T.
    Oganov, R.
    Lautsch, D.
    Ashton, V.
    Ambegaonkar, B.
    EUROPEAN HEART JOURNAL, 2015, 36 : 286 - 286
  • [43] ONLY EIGHT PERCENT OF VERY HIGH-RISK FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS ACHIEVE LDL-CHOLESTEROL TARGET DESPITE BEING ON MAXIMAL CONVENTIONAL LIPID-LOWERING THERAPY
    Bogsrud, Martin Proven
    Graedal, Asgeir
    Johansen, Dan
    Langslet, Gisle
    Hovland, Anders
    Holven, Kirsten
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1714 - 1714
  • [44] Failure of LDL-C goals achievement and underuse of lipid-lowering therapies in patients at high and very high cardiovascular risk: Spanish subset from the European SANTORINI study
    Mostaza, J. M.
    Garcia-Ortiz, L.
    Tembra, M. A. Suarez
    Calle, P. Talavera
    Garcia, J. Chimeno
    Perez, V. Escolar
    Diaz-Diaz, J. L.
    Manzano-Espinosa, L.
    Catapano, A. L.
    Ray, K. K.
    Moya, G. Diaz
    Montoya, J. Pedro-Botet
    REVISTA CLINICA ESPANOLA, 2025, 225 (02): : 78 - 84
  • [45] BURDEN OF CARDIOVASCULAR DISEASE (CVD) FOR PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (FH) OR ATHEROSCLEROTIC CVD (ASCVD) AND THE IMPACT OF LOW DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) LOWERING IN TWO MIDDLE EAST COUNTRIES
    Mahmeed, W. A.
    Habib, M.
    Villa, G.
    Qian, Y.
    Xiang, M.
    Fox, K. M.
    Coggia, A.
    Al-Ahdab, O.
    AlHabib, K. F.
    VALUE IN HEALTH, 2017, 20 (09) : A610 - A610
  • [46] BURDEN OF CARDIOVASCULAR DISEASE (CVD) FOR PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (FH) OR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) AND THE IMPACT OF REDUCING LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LOWERING IN LATIN AMERICAN COUNTRIES
    Vianna, D.
    Habib, M.
    Villa, G.
    Qian, Y.
    Xiang, P.
    Bahia, L. R.
    Alves, F. P.
    Alva, M. E.
    Ruiz Morales, A.
    Verdejo Paris, J.
    VALUE IN HEALTH, 2017, 20 (09) : A611 - A611
  • [47] LDL-C target attainment and statin use in patients with ASCVD, familial hypercholesterolaemia, and those otherwise at moderate/high-risk of ASCVD in australian general practice (SCOPE-GP)
    Watts, G. F.
    Audehm, R.
    Hespe, C.
    Liew, D.
    Berry, P.
    Chin, K. L.
    Rahman, M.
    Santani, R.
    Sciascia, C.
    Tonkin, A.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [48] Extremely high-risk patients with acute coronary syndrome: How "extreme" should lipid-lowering therapy be if the LDL-C target <40 mg/dl is considered?
    Rallidis, Loukianos S.
    Tsamoulis, Donatos
    Leventis, Ioannis
    Kalogeras, Petros
    Delakis, Iosif
    Samiotis, Elefterios
    Kalantzis, Charalampos
    Malkots, Belkis
    Tasoulas, Dimitrios
    Bouratzis, Vasileios
    Eleutheriou, Dimitris
    Dalos, Styliano
    Potoupni, Victoria
    Zervakis, Stelio
    Xygka, Georgia
    Miliotou, Argyro
    Papathanasiou, Konstantinos A.
    Vlachopoulos, Charalambos
    KARDIOLOGIA POLSKA, 2023, 81 (10) : 1012 - 1014
  • [49] Effectiveness of rosuvastatin in LDL-C lowering and national cholesterol education program (NCEP) adult treatment panel (ATP) III goal attainment compared to other statins among diabetes patients
    Fox, Kathleen M.
    Gandhi, Sanjay K.
    Ohsfeldt, Robert L.
    Blasetto, James
    Bays, Harold E.
    DIABETES, 2007, 56 : A620 - A620
  • [50] PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for allEditorial to: “Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/Dl or Higher” by Henry N. Ginsberg et Al.
    Evan A. Stein
    Cardiovascular Drugs and Therapy, 2016, 30 (5) : 427 - 431
12345